SG11202002192QA - Restoration of t cell activity via the cd39/cd73 axis - Google Patents

Restoration of t cell activity via the cd39/cd73 axis

Info

Publication number
SG11202002192QA
SG11202002192QA SG11202002192QA SG11202002192QA SG11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA
Authority
SG
Singapore
Prior art keywords
restoration
axis
cell activity
activity via
cell
Prior art date
Application number
SG11202002192QA
Other languages
English (en)
Inventor
Stéphanie Chanteux
Nicolas Gourdin
Carine Paturel
Ivan Perrot
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG11202002192QA publication Critical patent/SG11202002192QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
SG11202002192QA 2017-10-06 2018-10-05 Restoration of t cell activity via the cd39/cd73 axis SG11202002192QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US201862686143P 2018-06-18 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (1)

Publication Number Publication Date
SG11202002192QA true SG11202002192QA (en) 2020-04-29

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002192QA SG11202002192QA (en) 2017-10-06 2018-10-05 Restoration of t cell activity via the cd39/cd73 axis

Country Status (11)

Country Link
US (2) US20190218308A1 (pl)
EP (1) EP3692068B1 (pl)
JP (1) JP7274469B2 (pl)
KR (1) KR20200060471A (pl)
CN (1) CN111542539B (pl)
AU (1) AU2018346447A1 (pl)
BR (1) BR112020006809A2 (pl)
CA (1) CA3074588A1 (pl)
IL (1) IL273414A (pl)
SG (1) SG11202002192QA (pl)
WO (1) WO2019068907A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303828A1 (en) 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
BR112019018685A8 (pt) 2017-03-16 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
US20190062448A1 (en) 2017-07-31 2019-02-28 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
JP7471016B2 (ja) * 2019-08-21 2024-04-19 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｃｄ７３抗体およびその適用
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
CN114651013A (zh) * 2019-11-05 2022-06-21 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
EP4076669A4 (en) * 2019-12-19 2024-01-10 Board of Regents, The University of Texas System METHOD FOR TREATING GLIOBLASTOMA
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
EP4294846A1 (en) * 2021-02-19 2023-12-27 Janssen Biotech, Inc. Materials and methods for targeting regulatory t cells for enhancing immune surveillance
TW202340243A (zh) 2022-03-03 2023-10-16 美商阿克思生物科學有限公司 抗ｃｄ３９抗體及其用途
TW202409092A (zh) * 2022-06-08 2024-03-01 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ３９／ｃｄ７３雙特異性抗原結合蛋白及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
JP4361545B2 (ja) 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US20100303828A1 (en) * 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
AU2009213738B2 (en) 2008-02-11 2015-01-22 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2376535B9 (en) 2008-12-09 2017-09-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
HUE049647T2 (hu) 2009-11-24 2020-09-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
AU2013218017B2 (en) * 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
BR112017006464A2 (pt) * 2014-10-10 2018-01-30 Innate Pharma bloqueio de cd73
RS62003B1 (sr) 2014-11-10 2021-07-30 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
PE20170782A1 (es) 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
AU2016359790A1 (en) 2015-11-23 2018-06-21 Innate Pharma CD39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
JP7391510B2 (ja) 2015-12-09 2023-12-05 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
UA124529C2 (uk) 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018094148A1 (en) 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression
BR112019018685A8 (pt) * 2017-03-16 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
CN111372606B (zh) * 2017-11-15 2024-02-20 先天制药公司 增强atp释放作用
EP3959239A1 (en) * 2019-04-23 2022-03-02 Innate Pharma Cd73 blocking antibodies
CA3149494A1 (en) * 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells

Also Published As

Publication number Publication date
KR20200060471A (ko) 2020-05-29
BR112020006809A2 (pt) 2020-10-06
AU2018346447A1 (en) 2020-03-19
CN111542539B (zh) 2023-10-20
EP3692068B1 (en) 2022-12-07
JP2020536109A (ja) 2020-12-10
US20230099801A1 (en) 2023-03-30
US20190218308A1 (en) 2019-07-18
JP7274469B2 (ja) 2023-05-16
WO2019068907A1 (en) 2019-04-11
CN111542539A (zh) 2020-08-14
EP3692068A1 (en) 2020-08-12
IL273414A (en) 2020-05-31
CA3074588A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
IL273414A (en) Restoration of T cell activity through the CD39/CD73 axis
HK1254723A1 (zh) 主動式觸控筆環形電極
EP3601552A4 (en) POLYPEPTIDES WITH DNASE ACTIVITY
EP3349669A4 (en) STENT GRAFT
EP3322383A4 (en) Prosthetic heart valve
EP3429512A4 (en) FLEXIBLE ELEMENTS FOR ANCHORING THE BODY
IL268058A (en) Compositions and methods for depleting CD137 plus cells
SG11201610077TA (en) Active panel demarcation
EP3515467C0 (en) OPHTHALMIC COMPOSITION COMPRISING CICLOSPORINE
EP3600350A4 (en) BIOLOGICAL SCAFFOLDING INCLUDING THERAPEUTIC CELLS
EP3344156A4 (en) Implantable nuclear prosthesis
EP3651638A4 (en) IMAGING TO DETERMINE AN ELECTRODE GEOMETRY
GB2551933B (en) Paleogeographic reconstruction of an area of the earth crust
EP3624858A4 (en) HIGH ACTIVITY REGULATORY ELEMENTS
EP3677221A4 (en) COVERED STENT
EP3563809A4 (en) COVERED STENT
EP3243480A4 (en) Dental implant bolt fastening structure
EP3733120A4 (en) COVERED STENT
IL261891A (en) Active retinal implant
EP3656861A4 (en) ACTIVE MMP9-BINDING PEPTIDE
EP3256124A4 (en) Cenicriviroc for the treatment of fibrosis
EP3094347A4 (en) Methods for enhancing the delivery of active agents
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
EP3728562A4 (en) HEART MICROTISSUE AND ASSOCIATED USES
EP3648807A4 (en) COMPOSITIONS AND PROCEDURES FOR IMPROVING HEART FUNCTION